PET/CT in leukemia: utility and future directions-Reference-Cited by-同舟云学术

PET/CT in leukemia: utility and future directions

Published:2024-04-22 Issue:7 Volume:45 Page:550-563
ISSN:0143-3636
Container-title:Nuclear Medicine Communications
language:en
Short-container-title:

Author:

Al-Ibraheem Akram¹²,Allouzi Sudqi¹,Abdlkadir Ahmed Saad¹,Mikhail-Lette Miriam³,Al-Rabi Kamal⁴,Ma’koseh Mohammad⁴,Knoll Peter⁵,Abdelrhman Zaid⁴,Shahin Omar⁴,Juweid Malik E.⁶,Paez Diana³,Lopci Egesta⁷

Affiliation:

1. Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC),

2. Department of Radiology and Nuclear Medicine, School of Medicine, University of Jordan, Amman, Jordan,

3. Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria,

4. Department of Medical Oncology, King Hussein Cancer Center (KHCC), Amman, Jordan,

5. Dosimetry and Medical Radiation Physics Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria,

6. Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan and

7. Department of Nuclear Medicine, IRCCS – Humanitas Clinical and Research Hospital, Rozzano (MI), Italy

Abstract

2-Deoxy-2-[18F]fluoro-d-glucose PET/computed tomography ([18F]FDG PET/CT) has proven to be a sensitive method for the detection and evaluation of hematologic malignancies, especially lymphoma. The increasing incidence and mortality rates of leukemia have raised significant concerns. Through the utilization of whole-body imaging, [18F]FDG PET/CT provides a thorough assessment of the entire bone marrow, complementing the limited insights provided by biopsy samples. In this regard, [18F]FDG PET/CT has the ability to assess diverse types of leukemia The utilization of [18F]FDG PET/CT has been found to be effective in evaluating leukemia spread beyond the bone marrow, tracking disease relapse, identifying Richter’s transformation, and assessing the inflammatory activity associated with acute graft versus host disease. However, its role in various clinical scenarios in leukemia remains unacknowledged. Despite their less common use, some novel PET/CT radiotracers are being researched for potential use in specific scenarios in leukemia patients. Therefore, the objectives of this review are to provide a thorough assessment of the current applications of [18F]FDG PET/CT in the staging and monitoring of leukemia patients, as well as the potential for an expanding role of PET/CT in leukemia patients.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference139 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.;Sung;CA Cancer J Clin,2021

2. Regulation of hematopoietic and leukemic stem cells by the immune system.;Riether;Cell Death Differ,2015

3. World Health Organization classification of tumors of hematopoietic and lymphoid tissues, 2008 – major changes from the 3rd edition, 2001.;Zerbini;Rev Assoc Med Bras,2011

4. MRI and PET/MRI in hematologic malignancies.;Mayerhoefer;J Magn Reson Imaging,2020

5. Leukaemia: a model metastatic disease.;Whiteley;Nat Rev Cancer,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: 18F-FDG PET/CT skeletal superscan-like in an adult patient with acute lymphoblastic leukemia;Frontiers in Oncology;2024-07-15

2. 18F-Fluorodeoxyglucose-Avid Benign Anthracotic Mediastinal Lymphadenitis Mimicking Metastatic Lymphadenopathy;Cureus;2024-05-03

3. E-cigarette Use and Severe Coronavirus Disease 2019 (COVID-19) Outcomes: A Meta-Analysis;Cureus;2024-05-03